Deutsche Bank Reiterates Buy Rating on Spyre Therapeutics
Deutsche Bank maintains its Buy rating for Spyre Therapeutics with a price target of $135, a 52.25% upside from the current price.
Key Points
- Deutsche Bank reiterated its Buy rating on Spyre Therapeutics, Inc. (SYRE) with a price target of $135 as of June 23, 2026.
- Deutsche Bank's $135 price target implies 52.25% upside from Spyre Therapeutics, Inc.'s ($SYRE) current $88.67 share price.
- Shares of Spyre Therapeutics traded at $100.32 on Tuesday, with a market cap around $8.71 billion and a forward P/E of -32.17.
- Recent insider activity at Spyre includes multiple transactions by executives, with Chief Medical Officer Sloan Sheldon selling shares on June 3, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Deutsche Bank has reiterated its Buy rating on Spyre Therapeutics, Inc. (SYRE) as of June 23, 2026, maintaining a price target of $135. Spyre Therapeutics is a biotechnology company focused on developing treatments for inflammatory bowel disease and other rheumatic diseases.
Deutsche Bank vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Spyre Therapeutics
Several institutional investors have recently adjusted their holdings in Spyre Therapeutics. FMR LLC increased its stake by 142,205 shares, bringing its total to 11,781,024 shares valued at about $594.2 million, marking a 1.2% increase. BlackRock, Inc. slightly reduced its position by 880 shares, ending with 5,521,221 shares worth approximately $278.5 million. Perceptive Advisors LLC made a notable increase of 714,000 shares, growing its holdings by 23.3% to 3,783,225 shares valued at $190.8 million.
Spyre Therapeutics, Inc. Stock Down 1.9%
Shares of NasdaqGS:SYRE traded near $100.32 on Tuesday. Spyre Therapeutics has a market cap of approximately $8.71 billion and a forward P/E ratio of -32.17, indicating the company is not currently profitable. The stock's 52-week range is between $14.00 and $101.71, with a 50-day moving average of $72.73 and a 200-day moving average of $40.89. The company's beta is 3.063, suggesting higher volatility compared to the market.
$SYRE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Spyre Therapeutics, Inc.
Recent insider transactions at Spyre Therapeutics include several by Chief Medical Officer Sloan Sheldon, who executed planned sales of 8,333 shares at $75.00 each on June 3, 2026. Additionally, Sheldon made an unplanned acquisition of 8,333 shares at $27.46 on the same day. Chief Financial Officer Scott Burrows purchased 7,500 shares at $14.50 on June 1, 2026, and executed planned sales of the same number of shares at $71.06.
Analysts Set New Price Targets
On June 23, 2026, Deutsche Bank maintained its Buy rating on Spyre Therapeutics with a price target of $135. BTIG also maintained its Buy rating with a target of $112 on June 16, 2026. The overall analyst consensus is a strong buy, with a mean target price of $99.13 based on 15 analyst opinions.
About Spyre Therapeutics
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts. It focuses on developing innovative therapies for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes several monoclonal antibodies targeting different pathways involved in these diseases. Dr. Cameron Turtle serves as the CEO, leading a team of 112 employees.
Bottom Line
Spyre Therapeutics remains a focus for investors, with Deutsche Bank's reiterated Buy rating and a price target of $135 highlighting potential growth. Institutional and insider activities reflect ongoing interest and investment in the company. As a clinical-stage biotech firm, Spyre's future performance will be closely watched, especially as it approaches its next earnings report on August 4, 2026.
Get Spyre Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SYRE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.